Neumora TherapeuticsvsUnitedHealth

NMRA and UNH stock compared: price, dividend, valuation and results, from SEC filings.

NMRA

Neumora Therapeutics, Inc.

$0.33

Value $61M

-3.75%
NMRA's page

UNH

UnitedHealth Group Incorporated

$339.85

Value $308B

+2.84%
UNH's page

Neumora Therapeutics (NMRA) has a market value of $61M and UnitedHealth (UNH) $308B. Over the last year, with dividends, NMRA moved -86.9% and UNH +12.9%. Dividend yield: NMRA none, UNH 2.67%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    NMRA$61M

    UNH$308B

    UNH is 5,075 times NMRA

  • Revenue, 12 months

    NMRA–

    UNH$450B

  • Net income, 12 months

    NMRA-$190M

    UNH$15.9B

  • Operating margin

    NMRA–

    UNH5.3%

  • ROIC

    NMRA-87.2%

    UNH11.3%

    98.5 points apart

  • P/E

    NMRA–

    UNH19.4

  • Dividend yield

    NMRA0.0%

    UNH2.7%

    2.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

NMRA-97.2%

UNH-32.4%

050100150202420252026
Returns by period
PeriodNMRAWith dividendsUNHWith dividends
1 year since November 19, 2025-86.9%Price -86.9%+12.9%Price +10.0%
3 years since November 20, 2023-97.2%-69.6% a yearPrice -97.2%-32.4%-12.2% a yearPrice -36.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

NMRANeumora TherapeuticsUNHUnitedHealth

Valuation

NMRAUNH
Valuation
Price$0.33$339.85
Market value$61M$308B
Enterprise value (EV)$88M$354B
P/E–19.4
P/E, 5-year median–25.0
P/B3.33.0
EV/EBIT–14.8
Free cash flow yield–7.4%

Results and growth

NMRAUNH
Results and growth
Revenue, 12 months–$450B
Net income, 12 months-$190M$15.9B
Free cash flow, 12 months-$167M$22.8B
Earnings per share, 12 months-$1.06$17.52
Revenue growth, year on year–11.8%
Revenue growth a year, past–+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

NMRAUNH
Margins and returns on capital
Gross margin–88.3%
Operating margin–5.3%
Net margin–3.5%
ROIC-87.2%11.3%
ROE-257.5%15.5%

Balance sheet

NMRAUNH
Balance sheet
Cash$86M$28.5B
Total debt$114M$74.3B
Net debt / EBITDA–1.6
Interest cover-44.1×6.2×

Dividends and buybacks

NMRAUNH
Dividends and buybacks
Dividend yield–2.7%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.8%
Shareholder yield–4.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: NMRA or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Neumora Therapeutics or UnitedHealth?

By market value, UnitedHealth ($308B) is about 5,075.0 times Neumora Therapeutics ($61M), at today's prices.

How did NMRA and UNH stock do over the last 3 years?

Since November 20, 2023, NMRA's price moved -97.2% and UNH's -36.5%. With dividends: NMRA -97.2% (-69.6% a year), UNH -32.4% (-12.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, NMRA or UNH?

The dividend yield at today's price is none for Neumora Therapeutics and 2.67% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which is the better investment, Neumora Therapeutics or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.